{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=32",
    "query": {
      "intervention": "Injectable Placebo",
      "page": 32
    },
    "page_size": 10
  },
  "pagination": {
    "page": 32,
    "page_size": 10,
    "total_count": 4209,
    "total_pages": 421,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=33&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+Placebo&page=31&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-20T04:21:26.176Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03656380",
      "title": "Mepo for Eosinophilic Esophagitis (EoE) Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "EoE",
        "Eosinophilic Esophagitis"
      ],
      "interventions": [
        {
          "name": "Mepolizumab 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Mepolizumab 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "16 Years to 75 Years"
      },
      "enrollment_count": 66,
      "start_date": "2019-03-20",
      "completion_date": "2022-12-09",
      "has_results": true,
      "last_update_posted_date": "2023-08-23",
      "last_synced_at": "2026-10-20T04:21:26.176Z",
      "location_count": 4,
      "location_summary": "Chicago, Illinois • Minneapolis, Minnesota • Chapel Hill, North Carolina + 1 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03656380"
    },
    {
      "nct_id": "NCT06826196",
      "title": "A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Alopecia Areata (AA)"
      ],
      "interventions": [
        {
          "name": "ALD-102 Solution",
          "type": "DRUG"
        },
        {
          "name": "Placebo or Control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Aldena Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2025-03-24",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-03-04",
      "last_synced_at": "2026-10-20T04:21:26.176Z",
      "location_count": 4,
      "location_summary": "Thousand Oaks, California • West Lafayette, Indiana • Boston, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Thousand Oaks",
          "state": "California"
        },
        {
          "city": "West Lafayette",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Spokane",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06826196"
    },
    {
      "nct_id": "NCT06496620",
      "title": "A Study to Evaluate Solrikitug in Participants With COPD (ZION)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COPD"
      ],
      "interventions": [
        {
          "name": "Biological: Solrikitug low dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biological: Solrikitug high dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Uniquity One (UNI)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 182,
      "start_date": "2024-08-14",
      "completion_date": "2027-02-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-10-20T04:21:26.176Z",
      "location_count": 94,
      "location_summary": "Birmingham, Alabama • Sheffield, Alabama • Peoria, Arizona + 82 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Sheffield",
          "state": "Alabama"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06496620"
    },
    {
      "nct_id": "NCT02334423",
      "title": "A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glabellar Frown Lines"
      ],
      "interventions": [
        {
          "name": "Botulinum toxin, Type A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "0.9% sterile, unpreserved saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Evolus, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 330,
      "start_date": "2015-01",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2019-03-27",
      "last_synced_at": "2026-10-20T04:21:26.176Z",
      "location_count": 1,
      "location_summary": "Boca Raton, Florida",
      "locations": [
        {
          "city": "Boca Raton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02334423"
    },
    {
      "nct_id": "NCT02326220",
      "title": "Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Heterozygous Familial Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Alirocumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2015-03-31",
      "completion_date": "2016-04-30",
      "has_results": true,
      "last_update_posted_date": "2020-05-01",
      "last_synced_at": "2026-10-20T04:21:26.176Z",
      "location_count": 7,
      "location_summary": "Aurora, Colorado • Hartford, Connecticut • Kansas City, Kansas + 4 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Scarborough",
          "state": "Maine"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02326220"
    },
    {
      "nct_id": "NCT05666310",
      "title": "Muscle Impact of Treating Osteoporosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Sarcopenia",
        "Osteoporosis"
      ],
      "interventions": [
        {
          "name": "Denosumab",
          "type": "DRUG"
        },
        {
          "name": "Zoledronic Acid",
          "type": "DRUG"
        },
        {
          "name": "Denosumab Placebo",
          "type": "OTHER"
        },
        {
          "name": "Zoledronic Acid Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Nami Safai Haeri",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "65 Years and older · Female only"
      },
      "enrollment_count": 20,
      "start_date": "2023-02-14",
      "completion_date": "2026-09-05",
      "has_results": false,
      "last_update_posted_date": "2026-01-12",
      "last_synced_at": "2026-10-20T04:21:26.176Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05666310"
    },
    {
      "nct_id": "NCT05092646",
      "title": "Evaluating Intra-articular Injection of Axolotl Ambient Compared to Saline in Subjects With Ankle Osteoarthritis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ankle Osteoarthritis"
      ],
      "interventions": [
        {
          "name": "Axolotl Ambient",
          "type": "BIOLOGICAL"
        },
        {
          "name": "\"Drug/Placebo: 0.9% Normal Saline\"",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Axolotl Biologix",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 12,
      "start_date": "2021-12-01",
      "completion_date": "2023-11-10",
      "has_results": true,
      "last_update_posted_date": "2026-08-07",
      "last_synced_at": "2026-10-20T04:21:26.176Z",
      "location_count": 3,
      "location_summary": "Boise, Idaho • Shreveport, Louisiana • Charlotte, North Carolina",
      "locations": [
        {
          "city": "Boise",
          "state": "Idaho"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05092646"
    },
    {
      "nct_id": "NCT05856526",
      "title": "A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Netherton Syndrome"
      ],
      "interventions": [
        {
          "name": "Spesolimab - solution for infusion",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching to spesolimab - solution for infusion",
          "type": "DRUG"
        },
        {
          "name": "Spesolimab - solution for injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching to spesolimab - solution for injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2023-06-12",
      "completion_date": "2025-07-31",
      "has_results": true,
      "last_update_posted_date": "2026-03-12",
      "last_synced_at": "2026-10-20T04:21:26.176Z",
      "location_count": 4,
      "location_summary": "Rancho Santa Margarita, California • New Haven, Connecticut • Charleston, South Carolina + 1 more",
      "locations": [
        {
          "city": "Rancho Santa Margarita",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        },
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05856526"
    },
    {
      "nct_id": "NCT01775358",
      "title": "Phase 1 Safety Study of ALRN-5281 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Growth Hormone Deficiency"
      ],
      "interventions": [
        {
          "name": "ALRN-5281 0.015 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "ALRN-5281 0.05 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "ALRN-5281 0.15 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Placebo 0.015 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Placebo 0.05mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Placebo 0.15mg/kg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aileron Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "20 Years to 50 Years"
      },
      "enrollment_count": 33,
      "start_date": "2013-01",
      "completion_date": "2013-05",
      "has_results": false,
      "last_update_posted_date": "2013-05-30",
      "last_synced_at": "2026-10-20T04:21:26.176Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01775358"
    },
    {
      "nct_id": "NCT00439335",
      "title": "Higher Dose Intradermal H5 Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Inactivated Influenza A Vaccine A/H5N1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (IM)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (ID)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 227,
      "start_date": "2007-03",
      "completion_date": "2008-02",
      "has_results": true,
      "last_update_posted_date": "2013-04-09",
      "last_synced_at": "2026-10-20T04:21:26.176Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00439335"
    }
  ]
}